Raymond James & Associates Acquires 12,873 Shares of InflaRx (NASDAQ:IFRX)

Raymond James & Associates raised its holdings in InflaRx (NASDAQ:IFRX) by 7.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 175,279 shares of the company’s stock after acquiring an additional 12,873 shares during the period. Raymond James & Associates’ holdings in InflaRx were worth $286,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IFRX. Raymond James Financial Services Advisors Inc. boosted its stake in shares of InflaRx by 45.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 268,915 shares of the company’s stock valued at $801,000 after purchasing an additional 84,178 shares in the last quarter. 683 Capital Management LLC increased its position in InflaRx by 17.5% during the 3rd quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock worth $7,003,000 after purchasing an additional 350,000 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in InflaRx by 35.3% in the 3rd quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock valued at $969,000 after purchasing an additional 84,897 shares during the last quarter. Finally, Alps Advisors Inc. boosted its position in InflaRx by 109.4% in the third quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock valued at $248,000 after buying an additional 43,501 shares in the last quarter. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Performance

NASDAQ:IFRX opened at $1.39 on Tuesday. InflaRx has a 52 week low of $1.14 and a 52 week high of $5.20. The firm’s fifty day moving average is $1.53 and its 200-day moving average is $1.58. The firm has a market cap of $81.85 million, a P/E ratio of -1.62 and a beta of 1.27.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). As a group, sell-side analysts anticipate that InflaRx will post -1 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of InflaRx in a report on Friday, March 22nd.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.